PMID: 28717533
AARDEX is the only mature, robust and proven adherence solution on the market today, one that maximises the reward, mitigates the risk and delivers resolution for your clinical trial
In pre- and postnatal development studies in pregnant rats, empagliflozin was administered from gestation day 6 through to lactation day 20 (weaning) at up to 100 mg/kg/day (approximately 16-times the 25 mg maximum clinical dose) without maternal toxicity
our cattle never receive hormones
Mobile phase: A-phase, acetonitrile/water (60/40, V/V) (containing 0.1% formic acid, 10 mmol/L ammonium formate)
Confidence-Boosting Effects : Beyond its functional benefits, GHK-CU empowers users with improved appearance, positively impacting self-esteem and confidence